Change search
ReferencesLink to record
Permanent link

Direct link
Twenty years with monoclonal antibodies: State of the art--Where do we go?
Umeå University, Faculty of Medicine, Department of Clinical Microbiology, Immunology/Immunchemistry.
Show others and affiliations
1996 (English)In: Acta Oncologica, ISSN 0284-186X, E-ISSN 1651-226X, Vol. 35, no 3, 259-265 p.Article in journal (Refereed) Published
Abstract [en]

In this review, we have selected some parameters with the potential to improve the efficacy of RIL and RIT. Focus has partially been on the behaviour of radiolabelled antibodies in vivo in relation to properties and amounts of both target antigen and the antibodies used. If, out of the 28 factors listed in Table 1, some should be given preference in future work, it is our opinion that after the initial saturation of the tumour site a rapid decrease in redundant antibody is of significant importance. Furthermore, quantitative aspects of both antigens and antibodies should be more carefully evaluated when possible. By combining several of the listed approaches toward increasing efficiency, a more extensive use of RIL and RIT could be expected in the future.

Place, publisher, year, edition, pages
1996. Vol. 35, no 3, 259-265 p.
URN: urn:nbn:se:umu:diva-41915PubMedID: 8679254OAI: diva2:408121
Available from: 2011-04-04 Created: 2011-04-04 Last updated: 2011-04-04

Open Access in DiVA

No full text


Search in DiVA

By author/editor
Stigbrand, TorgnyRiklund, KatrineHietala, Sven-Ola
By organisation
Immunology/ImmunchemistryDiagnostic Radiology
In the same journal
Acta Oncologica

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 40 hits
ReferencesLink to record
Permanent link

Direct link